Home > Gastroenterology > Crohn's Disease > Infliximab
Infliximab is an advanced treatment option for Crohn's disease. It requires intravenous infusion and patients should respond within 14 weeks.
Test for tubeculosis and hepatitis B. Infliximab can cause reactivation of hepatitis B.
Loading doses are 5 mg/kg at 0,2, and 6 weeks. Afterwards, the maintenance dose is 5 mg/kg every 8 weeks.
Please consider an official gastroenterology consult and refer to the sources below.